Loading
KCNC2 (Voltage-gated potassium channel KCNC2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Contributes to the regulation of the fast action potential repolarisation and in sustained high-frequency firing in neurons of the central nervous system. Homotetramer channels mediate delayed-rectifier voltage-dependent potassium currents that activate rapidly at high-threshold voltages and inactivate slowly.
Open Targets scores its association with cancer at 0.51 (direct and indirect evidence; datatypes literature 0.14, genetic association 0.22, clinical 0.76).
In plain words · KCNC2 (Voltage-gated potassium channel KCNC2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNC2 (Voltage-gated potassium channel KCNC2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain.
No product in this corpus aims at KCNC2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNC2: RNA tissue enriched (brain 34 nTPM); no normal tissue stained high; highest cancer staining ovarian cancer (1 of 10 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNC2 tissue; Open Targets ENSG00000166006 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Haas et al, Mamm. Genome, 1993, "Localization of Shaw-related K+ channel genes on mouse and human chromosomes". Source.
Sources: HGNC HGNC:6234 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96PR1 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000166006 (association with cancer (MONDO_0004992) 0.51; (GraphQL API, CC0))
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Contributes to the regulation of the fast action potential repolarisation and in sustained high-frequency firing in neurons of the central nervous system. Homotetramer channels mediate delayed-rectifier voltage-dependent potassium currents that activate rapidly at high-threshold voltages and inactivate slowly. Forms tetrameric channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNC1, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Location: Cell membrane; Membrane; Perikaryon; Cell projection, axon (UniProt). Locus 12q21.1 (HGNC).
RNA: tissue enriched (brain 34 nTPM), detected in some normal tissues.
No normal tissue stained high.
RNA group enriched: Breast Invasive Carcinoma 6 pTPM, Prostate Adenocarcinoma 14 pTPM.
Medium only: breast cancer, cervical cancer, colorectal cancer, endometrial cancer.
HPA KCNC2 tissue · HPA KCNC2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNC2" OR ABSTRACT:"KCNC2" OR TITLE:"potassium voltage-gated channel subfamily C member 2" OR ABSTRACT:"potassium voltage-gated channel subfamily C member 2" OR TITLE:"Voltage-gated potassium channel KCNC2" OR ABSTRACT:"Voltage-gated potassium channel KCNC2" OR TITLE:"Kv3.2" OR ABSTRACT:"Kv3.2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNC2, not a curated reading list.